PROTECTIVE EFFECT OF THE PAF ANTAGONIST BN-52021 IN AN EXPERIMENTAL RENAL WARM ISCHEMIA MODEL

被引：24

作者：

TORRAS, J ^{[1
]}

BORDALBA, JR ^{[1
]}

SERON, D ^{[1
]}

MOLINER, R ^{[1
]}

CARRERA, M ^{[1
]}

VALLES, J ^{[1
]}

MARTINEZCASTELAO, A ^{[1
]}

ALSINA, J ^{[1
]}

GRINO, JM ^{[1
]}

机构：

[1] HOSP LLOBREGAT,HOSP BELLVITGE,DEPT NEPHROL,FEIXA LLARGA S-N,E-08097 BARCELONA,SPAIN

来源：

TRANSPLANT INTERNATIONAL | 1993年 / 6卷 / 04期

关键词：

BN-52021; KIDNEY TRANSPLANTATION; IN RATS; ISCHEMIA; RENAL;

D O I：

10.1007/BF00337106

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Platelet activating factor is involved in warm ischemic damage. We studied the effect of the PAF receptor antagonist BN 52021 in an experimental model of 60 min of renal warm ischemia in which the left kidney was flushed with Euro-Collins solution and a right nephrectomy was performed. Eighty Wistar rats were divided into a sham-operated group, two control groups, and four study groups, according to the dosage and route of BN 52021 administration. BN 52021 was used in the flush solution at concentrations of 0.1 and 0.5 mg/ml, or intravenously prior to ischemia at 5 and 10 mg/kg body weight. Creatinine clearance per 100 g body weight, fractional sodium excretion, and conventional histology were studied. Rats that received BN 52021 intravenously showed a significantly higher creatinine clearance than controls. Intravenous BN 52021 produced a higher acceleration of renal function recovery at 10 mg/kg than at 5 mg/kg body weight. Conventional histology was better in animals that received BN 52021 at 10 mg/kg body weight than in controls. Addition of BN 52021 to Euro-Collins flushing solution showed no protective effect. We conclude that intravenous BN 52021 shows a renal protective effect against warm ischemia.

引用

页码：236 / 238

页数：3

共 12 条

[1]

Braquet P., Touqui L., Shen T.Y., Vargaftig B.B., Perspectives in platelet activating factor research, Pharmacol Rev, 39, pp. 97-145, (1987)

[2]

Conte J.V., Katz N.M., Wallace R.B., Foegh M.L., Long-term lung preservation with the PAF antagonist BN 52021, Transplantation, 51, pp. 1152-1156, (1991)

[3]

Droy-Lefaix M.T., Drouet Y., Geraud G., Hosford D., Braquet P., Superoxide dismutase (SOD) and the PAF antagonist (BN 52021) Reduce small intestinal damage induced by ischemiareperfusion, Free Radic Res Commun, 12, pp. 725-735, (1991)

[4]

Hoelscher M., Klaess G., Kallerhoff M., Bretschneider H.J., Is Euro collins solution losing its protective ability, above 15°C?, Transplant Proc, 16, pp. 166-171, (1984)

[5]

Lopez Farre A., Torralbo M., Lopez Novoa J.M., Glomeruli from ischemic rat kidneys produce increased amounts of platelet activating factor, Biochemical and Biophysical Research Communications, 152, pp. 129-135, (1988)

[6]

Lopez Farre A., Bernabeu F., Gomez Garre D., Ramon y Cajal S., Braquet P., Lopez Novoa J.M., Platelet activating factor antagonist treatment protects against postischemic acute renal failure in rats, J Pharmacol Exp Ther, 253, pp. 328-333, (1990)

[7]

Lopez Farre A., Gomez Garre D., Bernabeu F., Montanes I., Millas I., Lopez Novoa J., Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF, Kidney International, 39, pp. 624-630, (1991)

[8]

Pirotzky E., Bidault J., Burtin C., Gubler M.C., Benveniste J., Release of platelet activating factor, slow reacting substance and vasoactive amines from isolated rat kidneys, Kidney Int, 25, pp. 404-411, (1984)

[9]

Santos J.C., Sanz E., Caramelo C., Hernando L., Lopez Novoa J.M., Effect of PAF-acether on renal function in dogs, Kidney Int, 28, (1985)

[10]

Santos O.F.P., Boim M.A., Bregman R., Draibe S.A., Barros E.J.C., Pirotzky E., Schor N., Braquet P., Effect of platelet activating factor antagonist on cyclosporine nephrotoxicity: glomerular hemodynamics evaluation, Transplantation, 47, pp. 592-595, (1989)

← 1 2 →